PMID- 34761470
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220301
IS  - 1386-6346 (Print)
IS  - 1386-6346 (Linking)
VI  - 52
IP  - 3
DP  - 2022 Mar
TI  - Safety and efficacy of atezolizumab plus bevacizumab in patients with 
      unresectable hepatocellular carcinoma in early clinical practice: A multicenter 
      analysis.
PG  - 269-280
LID - 10.1111/hepr.13732 [doi]
AB  - PURPOSE: To assess the impact of clinical factors on the safety and efficacy of 
      atezolizumab plus bevacizumab (ATZ + BV) treatment in patients with unresectable 
      hepatocellular carcinoma (u-HCC). METHOD: Ninety-four u-HCC patients who were 
      treated with ATZ + BV at multiple centers were enrolled. We defined Child-Pugh 
      (CP)-A patients who received ATZ + BV treatment as a first line therapy as the 
      'meets the broad sense of the IMbrave150 criteria' group (B-IMbrave150-in, 
      n = 46), and patients who received ATZ + BV treatment as a later line therapy or 
      CP-B patients (regardless of whether ATZ + BV was a first line or later line 
      therapy) as the B-IMbrave150-out group (n = 48). Patients were retrospectively 
      analyzed for adverse events (AEs) and treatment outcomes according to their 
      clinical characteristics, including neutrophil lymphocyte ratio (NLR) at 
      baseline. RESULTS: The overall incidence of AEs was 87.2% (82/94 patients). The 
      frequency of interruption of ATZ + BV treatment due to fatigue was higher in CP-B 
      than CP-A patients (p = 0.030). Objective response (OR) rates of the 
      B-IMbrave150-in group (28.3%, 39.1%) were significantly higher than those of the 
      B-IMbrave150-out group (8.3%, 18.8%; p = 0.0157, 0.0401) using Response 
      Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST, respectively. 
      In multivariate analysis, NLR (hazard ratio (HR), 4.591; p = 0.0160) and 
      B-IMbrave150 criteria (HR, 4.108; p = 0.0261) were independent factors associated 
      with the OR of ATZ + BV treatment using RECIST. CONCLUSION: In real-world 
      practice, ATZ + BV treatment might offer significant benefits in patients who 
      meet B-IMbrave150 criteria or have low NLR.
CI  - (c) 2021 Japan Society of Hepatology.
FAU - Chuma, Makoto
AU  - Chuma M
AD  - Gastroenterological Center, Yokohama City University Medical Center, Yokohama, 
      Japan.
FAU - Uojima, Haruki
AU  - Uojima H
AD  - Department of Gastroenterology, Internal Medicine, Kitasato University School of 
      Medicine, Sagamihara, Japan.
FAU - Hattori, Nobuhiro
AU  - Hattori N
AD  - Division of Gastroenterology and Hepatology, Department of Internal Medicine, St. 
      Marianna University School of Medicine, Kawasaki, Japan.
FAU - Arase, Yoshitaka
AU  - Arase Y
AD  - Division of Gastroenterology and Hepatology, Department of Internal Medicine, 
      Tokai University School of Medicine, Isehara, Japan.
FAU - Fukushima, Taito
AU  - Fukushima T
AD  - Hepatobiliary and Pancreatic Medical Oncology, Kanagawa Cancer Center Hospital, 
      Yokohama, Japan.
FAU - Hirose, Shunji
AU  - Hirose S
AD  - Division of Gastroenterology and Hepatology, Department of Internal Medicine, 
      Tokai University School of Medicine, Isehara, Japan.
FAU - Kobayashi, Satoshi
AU  - Kobayashi S
AUID- ORCID: 0000-0002-2535-6586
AD  - Hepatobiliary and Pancreatic Medical Oncology, Kanagawa Cancer Center Hospital, 
      Yokohama, Japan.
FAU - Ueno, Makoto
AU  - Ueno M
AD  - Hepatobiliary and Pancreatic Medical Oncology, Kanagawa Cancer Center Hospital, 
      Yokohama, Japan.
FAU - Tezuka, Shun
AU  - Tezuka S
AD  - Hepatobiliary and Pancreatic Medical Oncology, Kanagawa Cancer Center Hospital, 
      Yokohama, Japan.
FAU - Iwasaki, Shuichiro
AU  - Iwasaki S
AD  - Department of Gastroenterology, Internal Medicine, Kitasato University School of 
      Medicine, Sagamihara, Japan.
FAU - Wada, Naohisa
AU  - Wada N
AD  - Department of Gastroenterology, Internal Medicine, Kitasato University School of 
      Medicine, Sagamihara, Japan.
FAU - Kubota, Kousuke
AU  - Kubota K
AD  - Department of Gastroenterology, Internal Medicine, Kitasato University School of 
      Medicine, Sagamihara, Japan.
FAU - Tsuruya, Kota
AU  - Tsuruya K
AUID- ORCID: 0000-0002-9884-8039
AD  - Division of Gastroenterology and Hepatology, Department of Internal Medicine, 
      Tokai University School of Medicine, Isehara, Japan.
FAU - Shimma, Yoshimasa
AU  - Shimma Y
AD  - Division of Gastroenterology and Hepatology, Department of Internal Medicine, 
      Tokai University School of Medicine, Isehara, Japan.
FAU - Hiroki, Ikeda
AU  - Hiroki I
AD  - Division of Gastroenterology and Hepatology, Department of Internal Medicine, St. 
      Marianna University School of Medicine, Kawasaki, Japan.
FAU - Takuya, Ehira
AU  - Takuya E
AD  - Division of Gastroenterology and Hepatology, Department of Internal Medicine, St. 
      Marianna University School of Medicine, Kawasaki, Japan.
FAU - Tokoro, Chikako
AU  - Tokoro C
AD  - Division of Gastroenterology, Saiseikai Yokohamashi-Nanbu Hospital, Yokohama, 
      Japan.
FAU - Iwase, Shigeru
AU  - Iwase S
AD  - Department of Gastroenterology, Fujisawa City Hospital, Fujisawa, Japan.
FAU - Miura, Yuki
AU  - Miura Y
AD  - Gastroenterology Division, Hadano Red Cross Hospital, Hadano, Japan.
FAU - Moriya, Satoshi
AU  - Moriya S
AD  - Gastroenterological Center, Yokohama City University Medical Center, Yokohama, 
      Japan.
FAU - Watanabe, Tsunamasa
AU  - Watanabe T
AD  - Division of Gastroenterology and Hepatology, Department of Internal Medicine, St. 
      Marianna University School of Medicine, Kawasaki, Japan.
FAU - Hidaka, Hisashi
AU  - Hidaka H
AUID- ORCID: 0000-0002-4151-5663
AD  - Department of Gastroenterology, Internal Medicine, Kitasato University School of 
      Medicine, Sagamihara, Japan.
FAU - Morimoto, Manabu
AU  - Morimoto M
AD  - Hepatobiliary and Pancreatic Medical Oncology, Kanagawa Cancer Center Hospital, 
      Yokohama, Japan.
FAU - Numata, Kazushi
AU  - Numata K
AD  - Gastroenterological Center, Yokohama City University Medical Center, Yokohama, 
      Japan.
FAU - Kusano, Chika
AU  - Kusano C
AD  - Department of Gastroenterology, Internal Medicine, Kitasato University School of 
      Medicine, Sagamihara, Japan.
FAU - Kagawa, Tatehiro
AU  - Kagawa T
AD  - Division of Gastroenterology and Hepatology, Department of Internal Medicine, 
      Tokai University School of Medicine, Isehara, Japan.
FAU - Maeda, Shin
AU  - Maeda S
AD  - Department of Gastroenterology, Yokohama City University Hospital, Yokohama, 
      Japan.
LA  - eng
GR  - Yakult Honsha/
GR  - Chugai Pharmaceutical/
GR  - Astellas Pharma/
GR  - Taiho Pharmaceutical/
GR  - Eisai/
GR  - Ono Pharmaceutical/
GR  - 21K07899/JSPS KAKENHI/
PT  - Journal Article
DEP - 20211130
PL  - Netherlands
TA  - Hepatol Res
JT  - Hepatology research : the official journal of the Japan Society of Hepatology
JID - 9711801
OTO - NOTNLM
OT  - adverse events
OT  - atezolizumab plus bevacizumab
OT  - hepatocellular carcinoma
OT  - immune checkpoint inhibitor
OT  - molecular targeted agents
OT  - response
EDAT- 2021/11/12 06:00
MHDA- 2021/11/12 06:01
CRDT- 2021/11/11 07:18
PHST- 2021/10/23 00:00 [revised]
PHST- 2021/09/09 00:00 [received]
PHST- 2021/11/08 00:00 [accepted]
PHST- 2021/11/12 06:00 [pubmed]
PHST- 2021/11/12 06:01 [medline]
PHST- 2021/11/11 07:18 [entrez]
AID - 10.1111/hepr.13732 [doi]
PST - ppublish
SO  - Hepatol Res. 2022 Mar;52(3):269-280. doi: 10.1111/hepr.13732. Epub 2021 Nov 30.